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Abstract
Background: Dysregulation of signal transducer and activator of transcription 3 (STAT3) has been implicated as
a key participant in tumor cell survival, proliferation, and metastasis and is often correlated with a more malignant
tumor phenotype. STAT3 phosphorylation has been demonstrated in a subset of human osteosarcoma (OSA)
tissues and cell lines. OSA in the canine population is known to exhibit a similar clinical behavior and molecular
biology when compared to its human counterpart, and is often used as a model for preclinical testing of novel
therapeutics. The purpose of this study was to investigate the potential role of STAT3 in canine and human OSA,
and to evaluate the biologic activity of a novel small molecule STAT3 inhibitor.
Methods: To examine STAT3 and Src expression in OSA, we performed Western blotting and RT-PCR. OSA
cells were treated with either STAT3 siRNA or small molecule Src (SU6656) or STAT3 (LLL3) inhibitors and cell
proliferation (CyQUANT), caspase 3/7 activity (ELISA), apoptosis (Western blotting for PARP cleavage) and/or
viability (Wst-1) were determined. Additionally, STAT3 DNA binding after treatment was determined using
EMSA. Expression of STAT3 targets after treatment was demonstrated with Western blotting, RT-PCR, or gel
zymography.
Results: Our data demonstrate that constitutive activation of STAT3 is present in a subset of canine OSA tumors
and human and canine cell lines, but not normal canine osteoblasts. In both canine and human OSA cell lines,
downregulation of STAT3 activity through inhibition of upstream Src family kinases using SU6656, inhibition of
STAT3 DNA binding and transcriptional activities using LLL3, or modulation of STAT3 expression using siRNA,
all resulted in decreased cell proliferation and viability, ultimately inducing caspase-3/7 mediated apoptosis in
treated cells. Furthermore, inhibition of either Src or STAT3 activity downregulated the expression of survivin,
VEGF, and MMP2, all known transcriptional targets of STAT3.
Conclusion: These data suggest that STAT3 activation contributes to the survival and proliferation of human and
canine OSA cells, thereby providing a potentially promising target for therapeutic intervention. Future
investigational trials of LLL3 in dogs with spontaneous OSA will help to more accurately define the role of STAT3
in the clinical setting.
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Background
Signal transducers and activators of transcription (STAT)
proteins comprise a family of transcription factors that play
important roles in cell survival, growth, proliferation, dif-
ferentiation, apoptosis, metastasis, and angiogenesis [1-3].
Accumulating evidence suggests that constitutively acti-
vated STAT3 contributes to tumor development and pro-
gression in numerous forms of cancer including those of
the breast, head and neck, prostate, skin, ovary, lung, bone,
and blood [3-5]. Constitutively activated STAT3 correlates
with a more malignant tumor phenotype, resistance to
chemotherapeutics, and is associated with decreased sur-
vival in some cancers [6-8]. As such, STAT3 may represent a
novel target for therapeutic intervention in several cancers.
In support of this, a variety of inhibitors of STAT3 have
been shown to inhibit tumor cell growth and induce apop-
tosis both in vitro and in vivo [1,9,10]. Interestingly, STAT3
is not required for the proliferation of normal cells, and
multiple studies have demonstrated that normal cells are
more tolerant of loss of STAT3 function. [11].
Constitutive phosphorylation of STAT3 is thought to
occur via aberrant upstream signaling, as no naturally
occurring activating mutations in the STAT3 gene have
been identified [9]. STAT3 is phosphorylated following
stimulation of receptor tyrosine kinases by their respective
growth factors (i.e, Met/HGF, Kit/SCF), binding of
cytokines to their receptors (IL-6, oncostatin M), and by
activation of nonreceptor tyrosine kinases such as the Src
family kinases (SFKs)[12]. In particular, the SFKs are
instrumental in multiple signaling pathways involved in
the initiation and/or progression of numerous forms of
cancer [13]. Indeed, STAT3 was identified as a phosphor-
ylated substrate of v-src [14] necessary for enabling v-src
induced adhesion-independence and malignant transfor-
mation [11,12]. STAT3 is now known to be a substrate for
SFK members including Fyn and Lyn in addition to Src
itself [12,15]. Furthermore, recent studies demonstrated
that SFK inhibition in various carcinoma tumor cell lines
resulted in loss of STAT3 activity [13].
Although the contribution of STAT3 to epithelial cancers
and hematologic malignancies has been described in
detail, little is known about the potential role of STAT3
dysregulation in sarcomas. One study found that STAT3
activation was present in approximately fifty percent of
Ewing sarcoma tissues as assessed by immunostaining
[16]. More recent work investigating the potential role of
STAT3 activation in pediatric sarcomas including osteosa-
rcoma (OSA), rhabdomyosarcoma, and Ewing sarcoma
demonstrated that constitutive STAT3 phosphorylation
occurs in a high percentage of these tumors [1]. Moreover,
STAT3 inhibition via a novel small molecule STAT3 inhib-
itor (STA-21) or a dominant negative form of STAT3
resulted in inhibition of proliferation and apoptosis of
sarcoma cell lines expressing high levels of phospho-
STAT3 [1]. With respect to OSA, approximately 20% of
tumors on an OSA tissue microarray were shown to
express high levels of phospho-STAT3 suggesting that this
dysregulation is not a consequence of adaptation to tissue
culture. As such, STAT3 may represent a target for thera-
peutic intervention in pediatric OSA.
The ability to rapidly advance therapeutics in pediatric OSA
is limited by the low incidence of this disease. However, new
therapies are critical as approximately 30–40% of affected
patients still die of disease, and no substantial improvement
in this outcome has occurred in over ten years. To study
human OSA, several animal models have been developed
including a variety of transgenic and xenograft rodent mod-
els [17-19]. While studies employing these models have
been informative, they do not truly recapitulate the biology
of OSA that occurs spontaneously in vivo.
OSA occurs in dogs with a frequency far greater than
humans (over 10,000 new cases per year in the United
States), and evidence suggests that canine OSA exhibits a
similar biology to its human counterpart including early
metastasis and dysregulated expression of ezrin, Met, and
Her2/Neu [20-22]. Additionally, recent work has found
that canine and pediatric OSA possess overlapping tran-
scriptional profiles, supporting the notion that these dis-
eases are similar at the molecular level. Indeed, canine
OSA has been used as a large animal spontaneous model
of the human disease to investigate the clinical efficacy of
immunotherapeutic approaches and the activity of an
IGF1 inhibitor among several others [23-25].
Given the similarities of canine and pediatric OSA, we
investigated the potential role of STAT3 in the canine dis-
ease. Our data demonstrate that constitutive activation of
STAT3 is present in a substantial subset of canine OSA
tumors and human and canine cell lines and that down-
regulation of STAT3 activity through inhibition of
upstream Src family kinases using a small molecule inhib-
itor (SU6656), direct inhibition of STAT3 DNA binding
and transcriptional activities using a novel small molecule
inhibitor (LLL3), or modulation of STAT3 expression
using siRNAs, all resulted in decreased cell proliferation
and viability, ultimately inducing caspase-3 mediated
apoptosis in treated cells. Furthermore, inhibition of
either Src or STAT3 activity downregulated the expression
of survivin, VEGF, and MMP2, all known transcriptional
targets of STAT3. These data suggest that STAT3 activation
contributes to the survival and proliferation of both
human and canine OSA, thereby providing a potentially
promising target for therapeutic intervention.
Methods
Cell Lines and Reagents
Canine OSA cell lines, OSA7, 8, 11 M, 16, 29, and 32 were
provided by Dr. Jaime Modiano (University of Minnesota,BMC Cancer 2009, 9:81 http://www.biomedcentral.com/1471-2407/9/81
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Minneapolis, MN). The canine D17 OSA cell line and
human OSA cell lines U2OS, SJSA and MG63 were pur-
chased from American Type Cell Culture Collection
(ATCC). The canine lines and human line SJSA were
maintained in RPMI-1640 supplemented with 10% fetal
bovine serum, non-essential amino acids, sodium pyru-
vate, penicillin, streptomycin, L-glutamine, and HEPES
(4-(2-hydroxethyl)-1-piperazineethanesulfonic acid) at
35°C, supplemented with 5% CO2. The remaining
human cell lines were cultured in DMEM with 10% FBS
and same supplements as listed for the canine lines. Nor-
mal canine osteoblasts (Cell Applications, Inc, San Diego,
CA) were cultured in canine osteoblast medium (also
from Cell Applications). The Src inhibitor, SU6656 was
purchased from EMD Chemicals (San Diego, CA). The
novel STAT3 small molecule inhibitor LLL3 (also known
as compound 1), an analog of the small molecule STAT3
inhibitor STA-21, was generously provided by P.K. Li
(College of Pharmacy, The Ohio State University, Colum-
bus, OH) [1,26,27]. Concentrations of LLL3 used in
experiments were determined after consultation with J.
Lin. Canine OSA tumor and normal muscle were obtained
from patients treated at The Ohio State University College
of Veterinary Medicine Teaching Hospital in compliance
with established hospital policies regarding sample collec-
tion as part of the Biospecimen Repository at the Teaching
Hospital. The protocol for sample collection was
approved by the OSU IACUC. Fresh tissue samples were
immediately flash frozen in liquid nitrogen and stored in
The Ohio State University College of Veterinary Medicine
Comparative Oncology Biospecimen Repository. These
tumors were evaluated by board certified veterinary
pathologists at The Ohio State University College of Vet-
erinary Medicine.
Western Blotting
To determine the effect of HGF stimulation on STAT3 and
Src phosphorylation in normal canine osteoblasts or OSA
cells, cells were collected, washed once with PBS, and re-
suspended in 1 mL PBS with 50 ng mL-1 rhHGF for 15
minutes or left untreated. To determine the effects of cul-
ture conditions on Src and STAT3 phosphorylation, 2–5 ×
106 OSA cells were serum starved for 2 hours while in sus-
pension or adherent culture, or left in serum-containing
media while in adherent conditions for 2 hours prior to
collection. To determine the downstream effects of Src
and STAT3 inhibition, 2 × 106 OSA cells were treated with
SU6656, LLL3, or DMSO and collected after 24, 48, or 72
hours or starved for 2 hours and treated for 2 hours with
DMSO or SU6656. Cells were collected then resuspended
in lysis buffer consisting of 20 mM Tris-HCl pH 8.0, 137
mM NaCl, 10% glycerol, 1% IPEGAL CA-630, 10 mM eth-
ylenediaminetetraacetic acid (EDTA), 1 mg mL-1 apro-
tinin, 1 mg mL-1 leupeptin, 1 mg mL-1 pepstatin A, 1 mM
phenylmethylsulphonyl fluoride, 1 mM sodium
orthovanadate, and 10 mM sodium fluoride (all from
Sigma, St. Louis, MO) for 1 hour at 4°C[28]. Additionally,
protein lysates were prepared from frozen canine normal
muscle or OSA tumor samples by pulverizing tissues in
liquid nitrogen and resuspending them in this same lysis
buffer with proteinase and phosphatase inhibitors. The
results of Western blotting for phosphorylated STAT3 for
these samples were from two separate blots. Due to lim-
ited sample availability, the Western blots from different
tumor samples were batched and run on 2 different occa-
sions and all samples could not be subsequently re-run
together on one blot. Following protein quantification via
the Bradford Assay, 50 to 100 ug protein was separated by
SDS-PAGE, and transferred to PVDF membranes. The
membranes were then incubated overnight with anti-p-
STAT3 (Y705, Cell Signaling Technology, Danvers, MA),
anti-p-Src (Y418, Invitrogen, Carlsbad, CA), anti-PARP
(BD Biosciences, San Jose, CA), anti-VEGF (Calbiochem,
Gibbstown, NJ), or anti-survivin antibody (Novus Biolog-
icals, Littleton, CO). The membranes were incubated with
appropriate horseradish peroxidase linked secondary
antibodies, washed, and exposed to substrate (SuperSig-
nal West Dura Extended Duration Substrate, Pierce, Rock-
ford, IL). Blots were stripped, washed, and reprobed for β-
actin (Santa Cruz Biotechnology, Santa Cruz, CA), total
STAT3 (Cell Signaling Technology, Danvers, MA) or total
Src (Cell Signaling Technology, Danvers, MA).
RT-PCR
For the Src family kinase (SFK) RT-PCR, RNA was
extracted from untreated canine OSA cells using TRIzol
reagent (Invitrogen, Carlsbad, CA) according to the man-
ufacturer's instructions. For determining levels of mRNA
for STAT3 downstream transcriptional targets VEGF and
MMP2, human and canine OSA cells were treated with
either DMSO, LLL3 (40 uM), or SU6656 (10 uM) for 72
hours and RNA extracted from cells in the same manner.
To generate cDNA, 2 μg of total RNA and the M-MLV
reverse transcriptase kit (Invitrogen, Carlsbad, CA) were
used according to the manufacturer's instructions. Next,
1/20 of the resultant cDNA was used for each PCR reac-
tion in a total volume of 25 μl. Primers designed and uti-
lized for canine SFK members were as follows: (forward/
reverse sequences) Src (5'-GGCCCTCTATGACTATGAG/
GGTGGTGAGGCGGTGGCACAGGC-3'); Fyn (5'-GCG-
GCCGGAGGCCAAGGACTC/GTCGCTCAGCATCTTT-
TCGG-3'); Yes (5'-GATGCTTGGGAAATCCCTCG/
GCAGCCCGAAGATCTCGGTG-3'); Lyn (5'-
GGTAGCCTTGTACCCCTATG/CTTAATAACATCACCAT-
GCACAGGGTC-3'); and GAPDH (5'-ACCACAGTCCAT-
GCCATCAC/TCCACCACCCTGTTGCTGTA-3'). The
annealing temperature utilized for Src and Fyn was 62°C
and 58°C was used for all other SFK member PCR reac-
tions. Primers designed and utilized for canine STAT3
transcriptional targets were as follows: (forward/reverseBMC Cancer 2009, 9:81 http://www.biomedcentral.com/1471-2407/9/81
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sequences) VEGF (5'-GTCCCAGGCTGCGCCTATGG/
GTTTAACTCAAGCTGCCTCGCC-3'); MMP2 (5'-GGA-
GACTCTCACTTTGATGACG/GGTGAAGGGGAA-
GACACAGGGG-3'); and GAPDH (5'-
ACCACAGTCCATGCCATCAC/TCCACCACCCTGTTGCT-
GTA-3'). Annealing temperatures for these reactions was
55°C. Primers designed and utilized for the human STAT3
transcriptional target VEGF and GAPDH were as follows:
(forward/reverse sequences) VEGF (5'-CCTGGTGGA-
CATCTTCCAGGAGTACCC/CTAATGCCCT-
GGAGCCTCCC-3') and GAPDH (5'-
ACCACAGTCCATGCCATCAC/TCCACCACCCTGTTGCT-
GTA-3'). An annealing temperature of 60°C was used for
all PCR reactions with human primers. All PCR products
were run on a 2% agarose gel with ethidium bromide and
visualized using the Alpha Imager system (Alpha Innotech
Corp, San Leandro, CA).
STAT3 siRNA transfection
Canine STAT3 small interfering RNA (siRNA) was
designed and produced using the Silencer siRNA Con-
struction kit (Ambion, Austin, TX) according to the man-
ufacturer's protocol. Sequences of template canine DNA
were as follows: Sense STAT3 siRNA: 5'-AACTCTCTGGTC-
GACAGTACTCCTGTCTC-3'; Antisense STAT3 siRNA: 5'-
AAAGTACTGTCGACCAGAGAGCCTGTCTC-3'; Sense
negative control scrambled siRNA: 5'-AAACGT-
GACACGTTCGGAGAACCTGTCTC-3'; Antisense negative
control scrambled siRNA: 5'-AATTCTCCGAACGTGT-
CACGTCCTGTCTC-3'. 7.5 × 104 OSA cells were plated
and left overnight in 1% serum-containing media. The
following day, the media was changed to Opti-MEM
media (Invitrogen, Carlsbad, CA) and either media alone,
STAT3 or negative control scrambled siRNA (50 pMol of
each siRNA) with transfection agent Lipofectamine 2000
(Invitrogen, Carlsbad, CA), or Lipofectamine 2000 alone
was added to cells according to manufacturer's protocol.
Transfection was repeated again at 48 hours. Cells were
collected and processed for Western blotting as described
above to detect levels of STAT3, VEGF, survivin, and beta-
actin 48 hours after initial transfection. Cell viability was
determined at 0, 72, and 96 hours after initial transfection
using WST-1 reagent according to the manufacturer's
instructions after plating OSA cells as described above
(Clontech, Mountain View, CO). Cell viability was calcu-
lated as a percentage of the control wells. Additionally,
levels of apoptosis were determined at 48 hours using the
SensoLyte® Homogeneous AMC Caspase- 3/7 Assay kit
(Anaspec Inc, San Jose, CA) as described below after har-
vesting cell lysate. Images of cells 72 hours post transfec-
tion were recorded using digital photography.
Detection of Apoptosis/Caspase 3,7 Activity
1.1 × 104 OSA cells were seeded in 96-well plates over-
night and incubated with media, DMSO, or increasing
concentrations of LLL3 or SU6656 for 24 hours. Wells
with media only were included as controls. Levels of cas-
pase- 3/7 activity were determined using the SensoLyte®
Homogeneous AMC Caspase- 3/7 Assay kit (Anaspec Inc,
San Jose, CA) according to manufacturer's instructions.
Briefly, caspase 3/7 substrate solution was added to all
wells and incubated prior to measuring fluorescence on a
SpectraMax microplate reader (Molecular Devices Corp,
Sunnyvale, CA) using excitation at 354 nm and emission
detection at 442 nm. Levels of caspase 3/7 activity were
reported after subtraction of fluorescence levels of wells
with media only.
EMSA
To confirm that SU6656 and LLL3 impair STAT3 DNA
binding, we used the Pierce LightShift Chemiluminescent
EMSA kit (Thermo Fisher Scientific Inc, Rockford, IL) that
employs a chemiluminescent detection system to detect
protein:DNA interactions according to manufacturer's
instructions. Briefly, nuclear protein from human and
canine OSA cell lines treated 72 hours with media,
DMSO, SU6656 10 uM, or LLL3 40 uM was collected
using the NucBuster™ Protein Extraction kit (EMD Chem-
icals Inc, Gibbstown, NJ). Binding reactions using equal
amounts of nuclear protein from each treatment group
were incubated for 20 minutes at room temperature with
DNA probes. The canine STAT3 DNA binding sequence in
the promoter for survivin (sense 5'-GCCTTGCATTCCCA-
GAAGGCCGCGG-3') was used for binding reactions for
canine OSA; the STAT3 binding sequence in the human
survivin promoter (sense 5'-GAGACTCAGTT-
TCAAATAAATAAATAAAC-3') was used for the human
OSA cell line. Both were purchased from Operon Biotech-
nologies (Huntsville, AL) in a biotinylated form. Reac-
tions with biotinylated target DNA only and nuclear
protein with biotinylated target DNA and excess unla-
belled target DNA to compete for binding were included.
STAT3 specificity was confirmed by incubation with 6 ug
of anti-STAT3 antibody (Santa Cruz Biotechnology Inc,
Santa Cruz, CA) to super-shift the protein-DNA complex.
Following gel electrophoresis, DNA was transferred to a
nylon membrane. The DNA was cross-linked and the
biotin-labeled DNA detected by chemiluminescence
according to manufacturer's instructions.
Cell proliferation
2 × 103 cells were seeded in 96-well plates overnight and
incubated with DMSO or increasing concentrations of
LLL3 or SU6656 with daily treatment. Each drug concen-
tration was performed in four replicate wells. Media was
removed at days 1, 3, and 5 and plates frozen at -80°C
overnight before processing with the CyQUANT® Cell Pro-
liferation Assay Kit (Molecular Probes, Eugene, OR)
according to manufacturer's instructions. Fluorescence
was measured with a SpectraMax microplate readerBMC Cancer 2009, 9:81 http://www.biomedcentral.com/1471-2407/9/81
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(Molecular Devices Corp, Sunnyvale, CA) with excitation
at 485 nm and emission detection at 530 nm. Cell prolif-
eration was calculated as a percentage of the control
(DMSO treated) wells.
Gel zymography
7.5 × 104 OSA cells were seeded in 6-well plates overnight
and incubated with media only, DMSO, or increasing
concentrations of SU6656 or LLL3 for 72 hours. Media
was collected and processed and gel zymography per-
formed as described previously [29]. Images were
recorded using the Alpha Imager system (Alpha Innotech
Corp, San Leandro, CA) and analyzed using Image J.
Statistical Analysis
All experiments were performed two to three times. Statis-
tical analysis of the data was performed using the Stu-
dent's t-test. P values of ≤ 0.05 were considered
statistically significant.
Results
STAT3 is constitutively phosphorylated in OSA tumor 
tissues and cell lines
STAT3 is known to be activated by various upstream
receptor and nonreceptor tyrosine kinases including the
Src family kinases (SFKs) and Met [12,30]. We previously
generated data suggesting that STAT3 and Src were consti-
tutively phosphorylated in a subset of canine OSA cell
lines (OSA8 and D17) and that this phosphorylation was
independent of Met signaling. To determine whether acti-
vation of the Src-STAT3 pathway is common in OSA cell
lines, we first evaluated OSA lines for evidence of Src and
STAT3 phosphorylation in the presence or absence of
HGF stimulation. As shown in Fig. 1A, both canine OSA
lines and the human OSA line U2OS exhibited constitu-
tive Src and STAT3 phosphorylation that was independent
of HGF stimulation. We next evaluated normal canine
osteoblasts for evidence of STAT3 phosphorylation. In
contrast to the malignant OSA lines, normal osteoblasts
did not exhibit STAT3 phosphorylation either before or
after HGF stimulation (Fig. 1A). To assess whether culture
conditions affected the status of STAT3 and Src, cells were
grown in suspension or adherent cultures and in the pres-
ence or absence of serum and again evaluated for protein
phosphorylation. The basal levels of p-STAT3 remained
unchanged despite variation in culture conditions in
nearly all human and canine OSA cell lines evaluated (Fig.
1B). Basal levels of p-Src were similarly unchanged in
most of human and canine OSA cell lines. Additionally,
Western blotting of protein lysates derived from fresh fro-
zen canine OSA tumor samples revealed STAT3 phospho-
rylation in 3/8 tumors (38%) as compared to normal
canine muscle (Fig. 1C). Interestingly, levels of total
STAT3 expression also varied among tumor samples. This
may have been due, in part, to variations in baseline
necrosis within the tumor specimens that influenced the
proportion of tumor cells to stroma/inflammatory cells.
As expected, VEGF was found to be present in all tumor
specimens analyzed (Fig. 1C). To begin to assess which Src
family members may be responsible for the observed
basal Src phosphorylation, we analyzed the expression of
Src Family Kinases (SFKs) in 5 canine OSA cell lines by RT-
PCR. Although there was some variation in expression lev-
els among the lines, Src, Fyn, Yes, and Lyn were com-
monly present (Fig 1D).
STAT3 siRNA induces downregulation of STAT3 and its 
downstream targets survivin and VEGF with subsequent 
loss of viability and apoptosis of canine OSA cells
We designed a small interfering RNA specifically for
canine STAT3 to determine the effect of STAT3 downregu-
lation in canine OSA cells. Expression of STAT3 48 hours
post transfection was significantly reduced in cells treated
with 50 pMol siRNA (Fig. 2A) as evidenced by Western
blotting. Additionally, expression of the downstream tar-
gets of STAT3, VEGF and survivin, was reduced in both
OSA cell lines tested. Downregulation of STAT3 and sur-
vivin correlated with a significant loss in viability after 72
and 96 hours and induction of caspase-3/7 activity after
48 hours in both cell lines treated with STAT3 siRNA
when compared to those treated with transfection reagent
Lipofectamine 2000 alone or scrambled control siRNA
(Fig. 2B and 2C). Furthermore, a marked reduction in cel-
lularity occurred at 72 hours post transfection with Stat3
siRNA when compared to cells receiving media alone or
scrambled siRNA (Fig. 2D).
SU6656 inhibits phosphorylation of Src and STAT3 in OSA 
lines
We next evaluated whether the small molecule Src inhibi-
tor SU6656 could inhibit phosphorylation of Src and ulti-
mately that of STAT3 in human and canine OSA cell lines.
As shown in Fig. 3, SU6656 downregulated phosphoryla-
tion of Src in all canine and human OSA cell lines tested.
Additionally, there was an associated downregulation of
STAT3 phosphorylation in all human and canine OSA cell
lines that corresponded to the loss of pSrc.
Downregulation of Src or STAT3 leads to decreased STAT3 
DNA binding
STAT3 is known to regulate the expression of many down-
stream targets important in tumor growth and survival
such as survivin and VEGF through its binding to specific
sequences in promoter regions of these target genes. To
determine whether inhibition of STAT3 activity blocks
STAT3 DNA binding activity in OSA cells, we used 2 dif-
ferent approaches. We first interfered with activation by
upstream Src using SU6656, as this compound induced a
concomitant decrease in pSTAT3 in OSA cells following
treatment. As shown in Fig. 4A, there was a dramatic lossBMC Cancer 2009, 9:81 http://www.biomedcentral.com/1471-2407/9/81
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of binding to the survivin promoter STAT3 binding
sequence in both the canine OSA8 line and human SJSA
line after exposure to SU6656 compared to cells treated
with DMSO alone. We next directly blocked STAT3 DNA
binding and transcriptional activities using a novel small
molecule inhibitor of STAT3, LLL3, derived from the pre-
viously characterized STA-21 (Fig. 4B) [1,26,27]. LLL3
binds to the side pocket of STAT3 in close proximity to the
pTyr705 binding site of the STAT3 monomer, but does
not directly bind to pTyr705 which is critical for dimeriza-
tion [26]. It inhibits STAT3-specific DNA binding activity
and STAT3 transcriptional activity (personal communica-
tion, J. Lin). As expected, there was a significant loss of
STAT3 binding to the STAT3 binding sequence found in
the survivin promoter in the OSA8 and SJSA lines follow-
ing incubation with LLL3 when compared to cells treated
with media or DMSO (Fig. 4B). This gel shift was lost
when either excess unlabelled competitor DNA probe or
Activation of Src and STAT3 in OSA cell lines and tissues Figure 1
Activation of Src and STAT3 in OSA cell lines and tissues. A) OSA cells and normal canine osteoblasts were serum 
starved then left untreated or stimulated with rhHGF (50 ng/ml). Protein lysates were generated and separated by SDS PAGE 
and Western blotting for pSTAT3 (Y705), pSrc (Y416), total Src, and total STAT3 was performed. B) OSA cell lines were 
serum starved for 2 hours while in suspension culture (S), serum starved for 2 hours while remaining adherent to tissue cul-
ture flasks (A), or left in 1% serum while adherent in flasks for 2 hours prior to collection (C). Protein lysates were generated 
and separated by SDS-PAGE and Western blotting for pSTAT3 (Y705), pSrc (Y416), total Src, and total STAT3 was performed. 
C) Fresh frozen canine OSA tumor tissues and control normal muscle tissue were processed for protein lysates. Protein was 
separated by SDS-PAGE and Western blotting for pSTAT3 (Y705), STAT3, VEGF, and β-actin was performed. D) RNA was 
collected from canine OSA cell lines and RT-PCR was performed for SFK members Src, Fyn, Yes, and Lyn as well as GAPDH 
as a control.
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STAT3 siRNA induces downregulation of STAT3 and its downstream targets with subsequent loss of viability and apoptosis of  canine OSA cells Figure 2
STAT3 siRNA induces downregulation of STAT3 and its downstream targets with subsequent loss of viability 
and apoptosis of canine OSA cells. A) Canine OSA cell lines OSA8 and OSA16 were transfected with Lipofectamine 2000 
alone, 50 pMol scrambled siRNA, or 50 pMol STAT3 siRNA and collected 48 hours post transfection. Protein lysates were 
generated and separated via SDS-PAGE. Western blotting for STAT3, VEGF, survivin and β-actin was performed. B) OSA8 and 
OSA16 were transfected with Lipofectamine 2000, scrambled siRNA, or STAT3 siRNA at 0 and 48 hours. Cell viability was 
assessed at 0, 72, or 96 hours post transfection using the Wst-1 assay. Values are reported as percentage of control wells. C) 
OSA8 and OSA16 were transfected with Lipofectamine 2000, scrambled siRNA, or STAT3 siRNA and generation of active cas-
pase-3/7 was assessed 48 hours post transfection using the SensoLyte® Homogeneous AMC Caspase-3/7 Assay kit. D) OSA8 
cells were left untreated or transfected with STAT3 siRNA or scrambled siRNA and evaluated by digital photography 72 hours 
post transfection. *p < 0.05
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STAT3 antibody was added to the binding reactions thus
verifying their specificity for STAT3.
Inhibition of Src or STAT3 decreases cell proliferation, 
induces caspase-3,7 dependent apoptosis, and 
downregulates survivin in OSA cell lines
Given the correlation between dysregulated STAT3 activa-
tion and tumor cell survival, we wanted to determine
whether inhibition of Src and STAT3 activity in OSA cell
lines affected their capacity to proliferate and survive.
Human and canine OSA cell lines were cultured with
SU6656 or LLL3 at increasing concentrations for 1, 3, or 5
days. Cell proliferation was assessed using the CyQUANT
assay and apoptosis was determined using the SensoLyte
Homogeneous AMC Caspase 3/7 Assay kit. Although
there was some variation in response among cell lines,
SU6656 and LLL3 caused a dose and time dependent loss
in cell proliferation in all human and canine OSA cell
lines (Fig. 5A and 5B). Significant increases in apoptosis as
evidenced by caspase 3,7 activity were observed in many
OSA cell lines even at 24 hours post treatment (Fig. 5A
and 5B). The induction of apoptosis was further con-
firmed by demonstration of PARP cleavage in OSA cell
lines treated with LLL3 or SU6656 for 24 and 48 hours
(Fig. 6A and 6B). At both time points, there was a dose
and time dependent corresponding decrease in survivin
expression in the canine (Fig. 6A) and human OSA cell
lines (Fig. 6B).
Inhibition of Src or STAT3 leads to loss of MMP2 and VEGF 
expression in OSA cells
STAT3 is known to regulate the transcription of MMP2, a
matrix metalloproteinase known to be important in
tumor cell migration and metastasis. Treatment of the
canine OSA8 and OSA32 cell lines with the STAT3 inhib-
itor LLL3 resulted in a significant reduction in MMP2
mRNA expression (Fig. 7A). Treatment of canine and
human OSA cell lines with SU6656 or LLL3 for 72 hours
resulted in a corresponding dose and time dependent
downregulation of both the proenzyme and active form
of MMP2 as assessed by gel zymography (Fig. 7B).
Changes in MMP2 band intensity following drug treat-
ment were quantified via densitometry using NIH Image J
(Fig. 7C).
Expression of VEGF, another transcriptional target of
STAT3 was analyzed after treatment with either the Src
inhibitor SU6656 or STAT3 inhibitor LLL3. As with
MMP2, treatment of OSA cell lines with LLL3 resulted in
a significant reduction in VEGF mRNA expression (Fig.
8A). This translated into a corresponding reduction of
VEGF protein expression in canine and human OSA cell
lines following exposure to either LLL3 or SU6656 for 72
hrs (Fig. 8B). These results demonstrate that inhibition of
STAT3 activity in OSA cells induces not only a direct bio-
logic effect on cell survival, but influences the expression
of key proteins critical in metastasis.
Discussion
The contribution of STAT3 to cancer has been widely con-
firmed by numerous studies demonstrating dysregulated
activation in a variety of human tumors such as breast,
lung, pancreatic, ovarian, skin, and renal carcinomas, as
well as many hematopoietic tumors [3-5]. Given the prev-
alence of STAT3 dysregulation in cancer, its role in pro-
moting cell cycle progression, cellular transformation,
and prevention of apoptosis, and its unique position
downstream of multiple activating tyrosine kinases,
STAT3 represents a potential target for therapeutic inter-
vention [31]. While the function of STAT3 in carcinomas
and hematopoietic neoplasia has been intensively stud-
ied, little is known about the potential role of STAT3 dys-
regulation in sarcomas. The most detailed work done to
date investigating the role of STAT3 in human sarcomas
revealed elevated levels of pSTAT3 in a subset of pediatric
sarcomas which included osteosarcomas (OSAs) [1] as
well as in OSA cancer stem cells [32]. The purpose of this
study was to investigate the role of STAT3 dysregulation in
OSA and to explore the biologic consequences of STAT3
inhibition in OSA cell lines.
SU6656 inhibits phosphorylation of Src and STAT3 in OSA lines Figure 3
SU6656 inhibits phosphorylation of Src and STAT3 in OSA lines. Canine and human OSA cell lines were serum 
starved then left untreated or incubated with SU6656 for 2 hours. Cells were collected and protein separated by SDS-PAGE, 
followed by Western blotting for pSrc (Y416), pSTAT3 (Y705), total Src, and total STAT3.
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Several animal models have been developed to study
human OSA including radiation-induced OSA in Sprague-
Dawley rats [19], subcutaneous [18] and orthotopic [17]
implantation of OSA cells in mice, as well as a variety of
transgenic mouse models that develop OSA spontane-
ously. While studies employing these models have been
informative, they do not truly recapitulate the biology of
OSA that occurs spontaneously in vivo, particularly with
respect to the development of appendicular OSA and
chemotherapy-resistant metastases.
While OSA is the most common malignant bone tumor in
children, it occurs with a far greater frequency in the
canine population (1000 cases per year compared to
greater than 10,000 cases per year in the United States).
Beyond clinical similarities such as tumor location and
chemotherapy resistance, canine and human OSA share
similar biologic features including early metastasis, dys-
regulated expression of ezrin, Met, and Her2/Neu, and
overlapping transcriptional profiles [20-22,28,33-35].
Spontaneous canine OSA has been used to evaluate novel
therapeutics such as liposome encapsulated muramyl
tripeptide, IGF-1R inhibitors, and more recently, rapamy-
cin. [23,36-39]. Together, these data support the idea that
canine OSA is a relevant, spontaneous, large animal
model of human OSA that closely recapitulates the biol-
ogy of human OSA. As such, we chose to evaluate both
human and canine OSA cell lines, as well as fresh canine
OSA tumors for evidence of STAT3 dysregulation as dem-
onstration of abnormalities in both species would lay the
foundation for preclinical testing of STAT3 inhibitors in
dogs with OSA.
Constitutive phosphorylation of Src and STAT3 was
detected by Western blotting in all human and canine
OSA cell lines tested despite alterations in culture condi-
tions as well as in a subset (38%) of fresh frozen OSA
derived from canine patients, but not in normal canine
osteoblasts. This finding supports previous studies in
which human OSA cell lines and 19% of tissue microarray
samples were positive for elevated STAT3 phosphoryla-
tion [1]. Indeed, all human and canine OSA cell lines
tested expressed survivin, MMP2 and VEGF, downstream
targets of STAT3 important in preventing apoptosis,
enhancing invasion, and promoting metastasis. Increased
expression of survivin has been associated with reduced
survival in OSA [40] as well as chemotherapy and radio-
therapy resistance. Expression of VEGF in OSA is also
strongly predictive for pulmonary metastasis and poor
prognosis [41]. These data support the notion that consti-
tutive activation of both Src and STAT3 is common in
both canine and human OSA.
Studies have shown that inhibition of STAT3 activation
through various methods such as RNA interference, dou-
ble-stranded decoy oligodeoxynucleotides, and small
molecule inhibitors results in decreased viability and
apoptosis of a variety of human tumor cell lines, includ-
Downregulation of Src or STAT3 leads to decreased STAT3  DNA binding Figure 4
Downregulation of Src or STAT3 leads to decreased 
STAT3 DNA binding. The human OSA cell line SJSA and 
canine OSA cell line OSA8 were incubated with media, 
DMSO, or drug (A) SU6656, B) LLL3) for 72 hours. Cells 
were harvested and nuclear protein isolated. Nuclear protein 
was added to binding reactions with labeled species specific 
DNA probes for the STAT3 recognition sequences located 
in the promoter for survivin in the presence or absence of 
unlabelled competitor probe. Additionally, anti-STAT3 anti-
body was added to nuclear protein from cells treated with 
media alone to demonstrate specificity of the binding reac-
tion. Reactions were separated on an acrylamide gel, trans-
ferred to a nylon membrane, and the DNA was crosslinked. 
The membranes were processed using the LightShift Chemi-
luminescent EMSA kit.BMC Cancer 2009, 9:81 http://www.biomedcentral.com/1471-2407/9/81
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Inhibition of Src or STAT3 leads to loss of OSA cell proliferation and apoptosis via the caspase 3,7 pathway Figure 5
Inhibition of Src or STAT3 leads to loss of OSA cell proliferation and apoptosis via the caspase 3,7 pathway. A) 
Canine or B) human OSA cell lines were treated with DMSO, SU6656, or LLL3 for 1, 3, or 5 days. Proliferation was analyzed 
using the CyQUANT cell proliferation assay kit. Apoptosis was assessed by measuring active caspase-3/7 using the SensoLyte® 
Homogeneous AMC Caspase-3/7 Assay kit. Proliferation values are listed as a percentage of DMSO control. *p < 0.05BMC Cancer 2009, 9:81 http://www.biomedcentral.com/1471-2407/9/81
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ing those derived from sarcomas [1,42-46]. Previous work
has shown that downregulation of STAT3 using a domi-
nant-negative form decreased viability of human OSA
cells resulting in induction of apoptosis [1]. Additionally,
STAT3 knockdown using RNA interference in colon can-
cer cell lines reduced survivin expression resulting in
anoikis [47]. Transfection of canine OSA cell lines with
STAT3 siRNA led to loss of STAT3, survivin, and VEGF
expression with subsequent decreases in cell proliferation
and induction of apoptosis through the caspase 3/7 path-
way. Similar effects were seen in both canine and human
OSA cell lines treated with the small molecule Src inhibi-
tor SU6656 and the novel small molecule STAT3 inhibitor
LLL3. These data are consistent with findings of previous
studies of STAT3 inhibition in human carcinoma and
leukemia cell lines.
Inhibition of Src or STAT3 leads to PARP cleavage and downregulates survivin expression in OSA cell lines Figure 6
Inhibition of Src or STAT3 leads to PARP cleavage and downregulates survivin expression in OSA cell lines. A) 
Canine or B) human OSA cell lines were treated for 24 or 48 hours with DMSO, SU6656, or LLL3. Cells were collected and 
protein lysates were separated via SDS-PAGE. Western blotting for survivin, PARP and β-actin was performed. The anti-PARP 
antibody utilized in our laboratory has been applied to experiments with canine cell lines and recognizes a 113 kDa intact PARP 
protein and a 23 kDa cleaved PARP fragment [53].
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Downregulation of Src or STAT3 leads to loss of MMP2 expression in OSA cells Figure 7
Downregulation of Src or STAT3 leads to loss of MMP2 expression in OSA cells. A) Canine OSA cell lines OSA8 
and OSA 32 were treated with DMSO or LLL3 (40 uM), for 72 hours. RNA was collected and RT-PCR was performed for 
MMP2 and GAPDH. B) Canine and human OSA cell lines were treated with DMSO, SU6656, or LLL3 for 72 hours. Media was 
collected and MMP2 was assessed via gel zymography. C) Gel zymography images were evaluated by densitometry using NIH 
Image J.
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Abrogation of STAT3 DNA binding in both human and
canine OSA cell lines after treatment with both inhibitors,
as shown by EMSA, delineates the mechanism of loss of
downstream target mRNA and protein expression. Inter-
estingly, the STAT3 small molecule inhibitor STA-21, the
compound from which LLL3 was derived, was found to
act in a similar manner, preventing STAT3 activity by
blocking dimerization, translocation into the nucleus,
and execution of its signaling pathway in breast cancer
cells at roughly the same concentration [27]. Treatment
with STA-21 suppressed cell growth, reduced cell number,
and induced apoptosis in human sarcomas through cas-
pase 3, 8, and 9 dependent pathways [1]. These results
support the notion that the biologic effects manifested in
OSA cell lines following either loss of total STAT3 or loss
of STAT3 DNA binding are directly related to downregula-
tion of various STAT3 transcriptional targets responsible
for survival.
To correlate the effects of Src family kinase inhibition with
STAT3 activation, we evaluated the effects of inhibition of
Src on OSA cell lines. Previous work has shown that the
small molecule SFK inhibitor SU6656 blocks the phos-
phorylation of Src, Fyn, Lyn, and Yes with approximately
equal potencies [48]. SU6656 has been shown to decrease
activation of STAT3 and subsequent downstream targets
in NIH3T3 cells resulting in cell cycle arrest and apoptosis
in human lung cancer cells [30,49]. Our data demon-
strated that not only are these SFK members expressed in
the canine OSA cell lines tested, but that inhibition of Src
phosphorylation in both human and canine OSA cell
lines with SU6656 abrogated Src signaling resulting in a
concomitant decrease in STAT3 phosphorylation. These
data suggest that Src contributes to activation of STAT3 in
the human and canine OSA cell lines and that inhibition
of Src represents another method for abrogating STAT3
activity in OSA. Indeed, small molecule SFK inhibitors
have been evaluated in human OSA and Ewing's sarcoma
resulting in suppression of tumor cell migration, apopto-
sis of tumor cell lines, and inhibition of tumor growth in
xenograft models [46,47,50-52]. Given the apparent role
of Src in STAT3 activation, it is possible that SFK inhibitors
are working, in part, through modulation of STAT3 phos-
phorylation.
Conclusion
Our data demonstrate that constitutive activation of
STAT3 is present in both canine and human OSA cell lines
and in a subset of canine OSA fresh tumor specimens.
Downregulation of STAT3 activity in OSA cell lines, either
VEGF expression is reduced after Src or STAT3 inhibition Figure 8
VEGF expression is reduced after Src or STAT3 inhibition. A) Canine OSA cell line OSA8 and human OSA cell line 
U2OS were treated with LLL3 for 72 hours. RNA was collected and RT-PCR was performed for VEGF and GAPDH. B) 
Canine and human OSA cell lines were treated with DMSO, SU6656, or LLL3 for 72 hours. Cells were collected and protein 
lysates were separated via SDS-PAGE. Western blotting for VEGF and β-actin was performed.
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directly or through Src inhibition reduced proliferation
and expression of STAT3 transcriptional targets, and
induced apoptosis through caspase-3/7 activation. Data
generated in both the canine and human OSA cell lines
were concordant, suggesting that dysregulation of STAT3
may be common in this disease. This work serves as the
foundation for future experiments with LLL3 and other
inhibitors of STAT3 both in mouse models of OSA with
eventual application in dogs with spontaneous OSA, as a
prelude to clinical work in children.
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